In last trading session, Compugen Ltd (NASDAQ:CGEN) saw 0.3 million shares changing hands with its beta currently measuring 2.97. Company’s recent per share price level of $2.10 trading at -$0.08 or -3.67% at ring of the bell on the day assigns it a market valuation of $188.03M. That closing price of CGEN’s stock is at a discount of -44.29% from its 52-week high price of $3.03 and is indicating a premium of 35.71% from its 52-week low price of $1.35.
For Compugen Ltd (CGEN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.08 in the current quarter.
Compugen Ltd (NASDAQ:CGEN) trade information
Upright in the red during last session for losing -3.67%, in the last five days CGEN remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $2.10 price level, adding 10.26% to its value on the day. Compugen Ltd’s shares saw a change of 37.25% in year-to-date performance and have moved -4.11% in past 5-day. Compugen Ltd (NASDAQ:CGEN) showed a performance of -11.76% in past 30-days.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 47.5% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -90.48% in reaching the projected high whereas dropping to the targeted low would mean a loss of -90.48% for stock’s current value.
Compugen Ltd (CGEN) estimates and forecasts
This year revenue growth is estimated to rise 31.12% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 17.47M for the same. And 1 analysts are in estimates of company making revenue of 5M in the next quarter. Company posted 33.46M and 2.56M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.14% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 66.67% while estimates for its earnings growth in next 5 years are of -3.82%.
Compugen Ltd (NASDAQ:CGEN)’s Major holders
SILVERARC CAPITAL MANAGEMENT, LLC is the top institutional holder at CGEN for having 1.5 million shares of worth $2.52 million. And as of 2024-06-30, it was holding 1.6766 of the company’s outstanding shares.
The second largest institutional holder is TAYLOR FRIGON CAPITAL MANAGEMENT LLC, which was holding about 1.31 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.4681 of outstanding shares, having a total worth of $2.21 million.
On the other hand, Delaware Group Equity Fds IV-Delaware Healthcare Fund and PFS Funds-Taylor Frigon Core Growth Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.02 shares of worth $2.14 million or 1.14% of the total outstanding shares. The later fund manager was in possession of 242.97 shares on Nov 30, 2024 , making its stake of worth around $0.51 million in the company or a holder of 0.27% of company’s stock.
